IDH2 and glioblastoma: In the 2021 WHO classification of central nervous system tumors, EGFR amplification, but not EGFRvIII expression, is a diagnostic criterion for GBM, IDH-wildtype, when histopathological criteria do not allow for definitive diagnosis [4].